

Disrupting Neurodegeneration with Cell-Based Precision



HOPE Neuron
Therapeutx

A non-drug, immune-reprogramming device-enabled platform for ALS, and other autoimmune neurodegenerative diseases.

July 2025

Disclaimer

This presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to an investment of securities in Hope-Neuron therapeutx, Inc, a Delaware corporation (the “Company”, “we”, “our” and “us”) and for no other purpose. This presentation is strictly confidential and is being furnished solely in reliance on applicable exemptions from the registration requirements under the U.S. Securities Act of 1933 (the “Act”). This presentation does not contain, nor does it purport to contain, a summary of all the material information concerning the Company or the terms and conditions of any potential investment in the Company. The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice.

The securities to be offered have not been approved or disapproved by the U.S. Securities and Exchange Commission (the “SEC”), or any other securities regulating body or agency, nor has any such authority, commission, or body passed on the accuracy or adequacy of this presentation. Any representation to the contrary is a criminal offense. The securities will be subject to restrictions on transferability and resale and may not be transferred or resold except as permitted under the Act and applicable state securities laws pursuant to registration or exemption therefrom. Investors should be aware that they may be required to bear the financial risks of an investment in the securities for an indefinite period of time. The securities will not be listed on any securities exchange or automated quotation system, and there is no obligation on the part of any person to make a market for the securities. No action has been made or will be taken that would permit a public offering of any securities in any jurisdiction in which action for that purpose is required. No offers, sales, resales or delivery of any securities or any distribution of any offering material relating to any securities may be made in or from any jurisdiction except in circumstances which will result in compliance with any applicable laws and regulations and which will not impose any obligation on the Company.

If and when you determine to proceed with discussions and investigations regarding a possible investment in the Company, you are urged to carry out independent investigations in order to determine your interest in investing in the Company. This presentation and any oral statements made in connection with this presentation are for informational purposes only and do not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any securities of the Company. Nothing herein shall be deemed to constitute investment, legal, tax, financial, accounting or other advice.

Forward-Looking Statements:

This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (“PSLRA”), including statements regarding our relationships with our partners, liquidity issues and risks inherent in funding, developing and obtaining regulatory approvals of commercially-viable and competitive products and treatments, the intent, belief or current expectations of us and members of our leadership team, as well as the assumptions on which such statements are based. Words such as “expects,” “plans,” “predicts,” “projects,” “will,” “may,” “anticipates,” “seeks,” “potential,” “believes,” “should,” “intends,” “would,” “could,” “estimates,” or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are subject to risks, uncertainties, and other factors, many of which are outside our control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. Further, forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update or revise any forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required by law. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Industry and Market Data:

Industry and market data used in this presentation have been obtained from third party industry publications and sources, including reports by market research firms. The Company has not independently verified the information and data obtained from these sources and cannot assure you of the data’s accuracy or completeness. This information and data is subject to change.



Our first target is ALS

ALS is brutal Current treatments don't stop the clock

every 90

minutes, someone is diagnosed—and someone dies—from ALS.

2-5

years median survival

90%

of ALS cases are sporadic with no known cause.

Why is HOPE Neuron Different?

A Breakthrough Approach to Neurodegenerative Disease

- Non-drug, non-stem-cell, immune-reset platform
- Root-cause targeting, not symptom suppression
- Scalable, outpatient, sterile/disposable, precision controlled closed-loop therapy
- Backed by science, protected by global IP



Our Breakthrough: SELANETx™ + Apoptogenic Immune Modulation (AIM) Platform

We're not treating symptoms. We're resetting the immune system

- SELANETx™ is a 30-minute, outpatient, blood-processing therapy.
- Uses hyperoxia and mechanotransduction to trigger apoptosis.
- Restores immune balance by shifting M1 "killer" cells to M2 "healer" cells.

Stressing device enabled
mechanotransduction enhanced
hyperoxia induces Apoptosis



*Apoptotic cells (ACs) secrete "find me" signals
for their removal*



M1 macrophage killer cells attract
and "eat" (phagocytize) ACs



*Phagocytized ACs digested to recycle phlogistically
i.e. A noninflammatory*



Phagocytized ACs signal an M1-
killing to M2-healing cell
homeostatic shift




*M1 - M2 shift coined Efferocytosis,
Effero: "to the grave"*



How It Works

A closed-loop system designed to teach the body to heal itself.



Draw



Process



Reinfuse

1. Whole blood drawn (~300mL) in sterile disposable vials
2. Hyperoxic stress triggers apoptosis
3. Treated reinfused blood stimulates efferocytosis and immune rebalancing

PROBLEM

Disease Induced Dysregulation


Over Expressed



M1 ↑

M1 Functions (Killer)

- Pro-inflammatory
- Neuronal Tissue destruction




M2 ↓


M2 Functions (Healer)

- Anti-inflammatory
- Re-regulation
- Neuron regeneration


SOLUTION



Apoptotic-Cell Efferocytosis



Macrophage



M1-M2 Ratio rebalancing
EXTENDS PATIENT LIFE



Proof of Concept: Preclinical Results

From preclinical to pivotal: It works -
and fast

Mice treated with SELanetx™ preserved
significant motor function

Confirmed M1 → M2 immune shift ($p < 0.008$)

Untreated ALS mice fell off treadbar - SELanetx™
-treated mice continued to live and run, run, run

**We didn't just slow decline,
*we reversed it***




[play video](#)




Business Model + Revenue Structure

Treatment-based partnership model model built for global scalability.



Projected revenue allocation



**includes:*

- *Recurring revenue from consumables and disposables*
- *Optional licensing model for global partnerships*



Why Now?

From Treadbar to Trial: The Moment is Here

- IRB Human trial partners identified and in place: Banner, Barrow, Indiana University School of Medicine
- Transgenic mouse (n=10 ALS) budgeted at \$700–\$850K
- First Step - Reg CF will fund commercial launch
- Reg A+ will provide up to \$75M for corporate development, technology & patent expansion, and commercialization

SELanetx™



Banner Health.



Market Need & Opportunity

Our initial target market is ALS with a potential revenue of \$1.8 billion by Dec 2028 and overlapping neurodegenerative mechanics that could lead to new indications.

SELanetx™ Market Penetration Potential & Gross Revenue Sensitivity Calculation

HOPE-Neuron's Allocation & Critical Path Sensitivity

Assumed target patient population by year end 2028: **ALS 34,000 Patients**

Projected Revenue Allocation


- 40% HOPE-Neuron
- 35% Provider
- 25% Distributor


Opportunity Timeline

First target ALS (&FDA approval submission) in partnership with leading US clinics.

Gross Treatment Revenue

Estimated \$40,000 per treatment, 3 treatments/year, Annual total: **\$120,00/ Patient**





Competitive Landscape

The first non-drug, immune-reset platform for ALS

Overview

- Pharma has spent over \$2B failing to deliver a durable ALS solution
- Amylyx, Biohaven, UCB, Clene, Denali, PTC, and Corcept all failed endpoints (2024–2025)
- Last approved ALS therapy (Relyvrio) reached a \$400M annual run rate after just four quarters of commercialization.

Closest Technology Comparison: Therakos

- FDA approved, \$270M in annual revenue
- Sold for \$1.3B (2015) and \$925M (2024)
- No overlap with HOPE-Neuron's target markets, inferior technology, significant side effects from drug component

HOPE-Neuron is drug-free, scalable, and rooted in immune reset



Science to HOPE

Built for Scale - Ready for the Clinic

Discovery Phase pre 2022

- Identified immune dysfunction as a key driver of ALS progression
- Developed SELanetx™ to rebalance immune activity
- Secured early seed funding
- Fabricated and tested first-generation device (v1.0)
- SOD1 ALS mouse trials showed 40% motor function improvement
- Developed AIM® platform for immune modulation
- Filed initial and secondary IP

Proof of Concept 2023-2024

- Fabricated and validated SELanetx™ device v1.0
- Validated M1-to-M2 immune shift in ALS mouse models
- Secured IRB collaboration with Indiana University
- Began planning with Gregory W. Fulton ALS Clinic (Barrow Institute)
- Expanded research scope to include Multiple Sclerosis and Parkinson's
- Engaged ethics boards to support compassionate-use trial design
- Initiated conversations with device manufacturing partners

Path to Scale + Commercialization 2025

- Design next mouse and human studies with research partners
- Forge relationships with key entities in our target markets
- Expand executive leadership to support path to commercialization

Expansion 2026

- Complete ALS transgenic pilot (n=10 ALS mouse models) and conduct initial Alzheimer's model proof of concept testing
- Conduct IRB human trial with dosing optimization
- Begin engineering partnership for nextgen device
- Prepare for broader indication targeting Alzheimer's
- Submit FDA application for approval of SELanetx™ for ALS



Mission-Led. Expert-Driven



Ronald Lane, PhD

**Founder & Executive
Chairman**

Neurobiologist and inventor of
the SELanetx™ platform.



Yansheng Du, PhD

**Lead, Preclinical
Transgenic Research**

Professor of Neurology,
Indiana University School of
Medicine.



Kara Wood

**VP of
Communications**

Corporate communications
expert and life sciences
entrepreneur



Mark Forney

**VP of Business
Development**

Specializing in high-growth,
scalable technology
applications



Karina Fedasz

Interim CFO

Leads regulatory and
registration efforts.



John Louf

**Chief Technology
Officer**

Leads technology
infrastructure, operations, and
IP expansion.



Intellectual Property & Defensibility

Globally protected technology targeting immune modulation.

Patents granted and pending across U.S., Japan, Canada, India, Australia

Covers proprietary hyperoxia gas-fluid contact reactor and mechanotransduction process

Future filings planned for device development and optimization

U.S. Patent No. 1171579 "GAS TREATMENT DELIVERY SYSTEMS AND METHODS"/October, 2022

Japan Patent No. 75297259 "GAS TREATMENT DELIVERY SYSTEMS AND METHODS"/July, 2024

U.S. Patent No 7,736,494 B2 Method of Use "OZONE DELIVERY SYSTEM INCLUDING A VARIABLE PITCH GAS-FLUID CONTACT DEVICE"

Int'l Pat App: PCT/US2010/001785 "TREATMENT OF INFLAMMATORY DISORDERS, CARDIOVASCULAR DISEASES AND ACUTE ISCHEMIC BRAIN STROKE WITH OZONE"

Int'l Pat App: PCT/US2017/047690 "GAS TREATMENT DELIVERY SYSTEM AND METHODS" (China, India, Canada, Australia)







HOPE Neuron
Therapeutx

We're not selling hope. We're building it

The problem is urgent. The market is massive.
The science is sound.

[Schedule A Meeting](#)
[Request Deck PDF](#)
[Contact us](#)



Every 90 min we lose a life to ALS

Join us on our mission to bring new HOPE



HOPE Neuron
Therapeutx